Nasal spray for multiple system atrophy (MSA) study
Part of Brain & nervous system clinical trials.
This trial tests a nasal spray called Foralumab for people with multiple system atrophy (MSA). The goal is to see if the spray can help reduce symptoms or slow the disease. It is for people who are otherwise healthy enough to safely participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of multiple system atrophy (MSA).
- You are between 30 and 85 years old.
- Your Parkinson's medications have been stable for at least 4 weeks before joining.
- You do not have other serious health problems like active infections, severe heart disease, or certain autoimmune conditions.
- You are willing and able to use a nasal spray and undergo MRI scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug called ALT001 for people with multiple system atrophy (MSA). It aims to see if the drug is safe and may help slow the disease.
This study tests a new antibody drug that targets a protein linked to multiple system atrophy (MSA). It aims to see if the drug is safe and may slow the disease, for people recently diagnosed.
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
This trial tests whether a medication called butylphthalide can help slow or improve symptoms of multiple system atrophy (MSA), a rare neurological condition that affects movement, balance, and automatic body functions. The study will measure how well the drug works and how safe it is for patients.
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.